207 related articles for article (PubMed ID: 15958584)
1. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
Golas JM; Lucas J; Etienne C; Golas J; Discafani C; Sridharan L; Boghaert E; Arndt K; Ye F; Boschelli DH; Li F; Titsch C; Huselton C; Chaudhary I; Boschelli F
Cancer Res; 2005 Jun; 65(12):5358-64. PubMed ID: 15958584
[TBL] [Abstract][Full Text] [Related]
2. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
3. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
4. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling.
Coluccia AM; Benati D; Dekhil H; De Filippo A; Lan C; Gambacorti-Passerini C
Cancer Res; 2006 Feb; 66(4):2279-86. PubMed ID: 16489032
[TBL] [Abstract][Full Text] [Related]
5. 4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors.
Berger DM; Dutia M; Birnberg G; Powell D; Boschelli DH; Wang YD; Ravi M; Yaczko D; Golas J; Lucas J; Boschelli F
J Med Chem; 2005 Sep; 48(19):5909-20. PubMed ID: 16161995
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
Puttini M; Coluccia AM; Boschelli F; Cleris L; Marchesi E; Donella-Deana A; Ahmed S; Redaelli S; Piazza R; Magistroni V; Andreoni F; Scapozza L; Formelli F; Gambacorti-Passerini C
Cancer Res; 2006 Dec; 66(23):11314-22. PubMed ID: 17114238
[TBL] [Abstract][Full Text] [Related]
7. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
8. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
[TBL] [Abstract][Full Text] [Related]
9. Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src.
Sakuma Y; Takeuchi T; Nakamura Y; Yoshihara M; Matsukuma S; Nakayama H; Ohgane N; Yokose T; Kameda Y; Tsuchiya E; Miyagi Y
J Pathol; 2010 Apr; 220(5):574-85. PubMed ID: 20146241
[TBL] [Abstract][Full Text] [Related]
10. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
11. Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitors.
Boschelli DH; Wang D; Wang Y; Wu B; Honores EE; Barrios Sosa AC; Chaudhary I; Golas J; Lucas J; Boschelli F
Bioorg Med Chem Lett; 2010 May; 20(9):2924-7. PubMed ID: 20363128
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.
Rabindran SK; Discafani CM; Rosfjord EC; Baxter M; Floyd MB; Golas J; Hallett WA; Johnson BD; Nilakantan R; Overbeek E; Reich MF; Shen R; Shi X; Tsou HR; Wang YF; Wissner A
Cancer Res; 2004 Jun; 64(11):3958-65. PubMed ID: 15173008
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
[TBL] [Abstract][Full Text] [Related]
15. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective profile of novel SRC kinase inhibitors in rodent models of cerebral ischemia.
Liang S; Pong K; Gonzales C; Chen Y; Ling HP; Mark RJ; Boschelli F; Boschelli DH; Ye F; Barrios Sosa AC; Mansour TS; Frost P; Wood A; Pangalos MN; Zaleska MM
J Pharmacol Exp Ther; 2009 Dec; 331(3):827-35. PubMed ID: 19741150
[TBL] [Abstract][Full Text] [Related]
17. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
18. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.
Rhodes N; Heerding DA; Duckett DR; Eberwein DJ; Knick VB; Lansing TJ; McConnell RT; Gilmer TM; Zhang SY; Robell K; Kahana JA; Geske RS; Kleymenova EV; Choudhry AE; Lai Z; Leber JD; Minthorn EA; Strum SL; Wood ER; Huang PS; Copeland RA; Kumar R
Cancer Res; 2008 Apr; 68(7):2366-74. PubMed ID: 18381444
[TBL] [Abstract][Full Text] [Related]
19. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
[TBL] [Abstract][Full Text] [Related]
20. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
Vultur A; Buettner R; Kowolik C; Liang W; Smith D; Boschelli F; Jove R
Mol Cancer Ther; 2008 May; 7(5):1185-94. PubMed ID: 18483306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
